Latest Research And Development News

Prescient Therapeutics (ASX:PTX) has opened a $7 million Share Purchase Plan at a significant discount to advance its lead cancer therapy PTX-100 beyond a pivotal Dose Optimisation Committee review in late 2026.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Aurora Labs posted a 36% increase in net loss to $5.1 million for FY2026 despite securing key defence contracts and partnerships. The company is transitioning from R&D to early commercialisation of its micro gas turbine propulsion systems, backed by a $5.5 million capital raise and government grants.

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

WhiteHawk Limited has secured strong progress on its U.S. Federal cyber resilience contract, received most of the initial A$356,000 payment, and is negotiating a potential A$2.12 million annual subscription. The company is also implementing a significant operating reset to reduce costs by A$1.24 million annually while expanding U.S. public-sector procurement access.

Amcor’s FY2026 results reflect the full impact of its 2025 Berry Global acquisition, with net sales soaring 57% to $23.5 billion and net income more than doubling to $1.1 billion. The company also announced a fiscal year-end change and a raised dividend.